Your browser is no longer supported. Please, upgrade your browser.
Settings
PETX Aratana Therapeutics, Inc. daily Stock Chart
PETX [NASD]
Aratana Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.91 Insider Own2.10% Shs Outstand49.20M Perf Week-0.92%
Market Cap265.68M Forward P/E- EPS next Y-0.28 Insider Trans-9.74% Shs Float46.44M Perf Month-7.53%
Income-39.40M PEG- EPS next Q-0.16 Inst Own69.00% Short Float4.84% Perf Quarter20.54%
Sales25.60M P/S10.38 EPS this Y-23.30% Inst Trans4.58% Short Ratio8.80 Perf Half Y6.30%
Book/sh2.02 P/B2.67 EPS next Y42.90% ROA-29.10% Target Price8.16 Perf Year-16.28%
Cash/sh1.22 P/C4.43 EPS next 5Y15.00% ROE-43.50% 52W Range3.67 - 7.28 Perf YTD2.66%
Dividend- P/FCF- EPS past 5Y-20.10% ROI-38.00% 52W High-26.37% Beta2.12
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin44.00% 52W Low46.05% ATR0.26
Employees87 Current Ratio3.00 Sales Q/Q-5.80% Oper. Margin- RSI (14)42.07 Volatility6.02% 4.86%
OptionableYes Debt/Eq0.32 EPS Q/Q46.60% Profit Margin- Rel Volume1.14 Prev Close5.40
ShortableYes LT Debt/Eq0.09 EarningsNov 01 BMO Payout- Avg Volume255.26K Price5.36
Recom1.70 SMA20-4.83% SMA50-1.20% SMA2009.72% Volume165,606 Change-0.74%
Aug-06-18Reiterated Stifel Buy $8 → $7
Mar-27-18Upgrade Stifel Hold → Buy $8
Mar-12-18Upgrade CL King Neutral → Buy
Dec-27-17Initiated CL King Neutral
Nov-17-17Initiated H.C. Wainwright Buy $10
Aug-25-17Reiterated Lake Street Buy $15 → $10
May-10-17Reiterated Stifel Buy $8 → $7
Sep-06-16Resumed Lake Street Buy $15
Aug-19-16Resumed Jefferies Buy
Mar-16-16Reiterated Stifel Buy $12 → $11
Feb-04-16Initiated Credit Suisse Outperform
Nov-30-15Reiterated Barclays Overweight $30 → $15
Sep-25-15Downgrade Craig Hallum Buy → Hold
Jul-29-15Initiated Lake Street Buy $28
Feb-25-15Reiterated Stifel Buy $19 → $23
May-14-14Reiterated Stifel Buy $30 → $22
Feb-10-14Initiated Barclays Overweight $30
Oct-25-13Reiterated Stifel Buy $13 → $33
Jul-25-13Initiated William Blair Outperform
Jul-23-13Initiated William Blair Outperform
Oct-11-18 08:55AM  Report: Exploring Fundamental Drivers Behind Seritage Growth Properties, Forrester Research, Chemours, MoSys, Malibu Boats, and Aratana Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-29-18 08:30AM  Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference PR Newswire
Aug-24-18 04:05PM  Edited Transcript of PETX earnings conference call or presentation 3-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-15-18 03:11PM  Activist investor is buying up stock in KC's fastest-growing company American City Business Journals
Aug-07-18 08:20AM  Factors of Influence in 2018, Key Indicators and Opportunity within GTT Communications, Hope, Black Knight, Safety Insurance Group, M.D.C., and Aratana Therapeutics New Research Emphasizes Economic Growth GlobeNewswire
Aug-03-18 06:30AM  Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 07:55PM  Aratana (PETX) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:47PM  Aratana: 2Q Earnings Snapshot Associated Press
04:05PM  Aratana Therapeutics Reports Second Quarter 2018 Financial Results PR Newswire
Jul-10-18 08:30AM  Aratana Therapeutics to Report Second Quarter 2018 Financial Results PR Newswire
Jun-26-18 01:26PM  When Will Aratana Therapeutics Inc (NASDAQ:PETX) Breakeven? Simply Wall St.
Jun-19-18 07:05AM  Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-01-18 08:30AM  Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion PR Newswire
May-22-18 04:05PM  Aratana Therapeutics to Participate at Jefferies 2018 Global Healthcare Conference PR Newswire
May-21-18 08:30AM  Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital PR Newswire
May-17-18 09:00AM  Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks ACCESSWIRE
May-08-18 10:05PM  Edited Transcript of PETX earnings conference call or presentation 4-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-05-18 12:01AM  [$$] Engaged Capital Seeks Seats on Aratana Therapeutics Board Barrons.com
May-04-18 06:15AM  Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-03-18 06:06PM  Aratana: 1Q Earnings Snapshot Associated Press
04:05PM  Aratana Therapeutics Reports First Quarter 2018 Financial Results PR Newswire
May-02-18 08:00AM  Recent Analysis Shows Waterstone Financial, Blue Bird, Proto Labs, American Assets Trust, MoSys, and Aratana Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-17-18 04:00PM  5 Drug Stocks Poised to Surpass on Earnings This Quarter InvestorPlace
Apr-12-18 08:30AM  Aratana Therapeutics to Report First Quarter 2018 Financial Results PR Newswire
Apr-05-18 09:29AM  Aratana Therapeutics Confirms Receipt of Board Nominations PR Newswire
Mar-28-18 08:39AM  Aratana Therapeutics (PETX) Soars: Stock Adds 12.4% in Session Zacks
Mar-27-18 12:10PM  Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade Benzinga +12.40%
Mar-20-18 08:00AM  New Research Coverage Highlights Home, Gorman-Rupp, Aratana Therapeutics, Washington Real Estate Investment Trust, XG Technology, and Hope Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-18-18 11:20AM  Edited Transcript of PETX earnings conference call or presentation 14-Mar-18 12:30pm GMT Thomson Reuters StreetEvents
Mar-14-18 04:00PM  Aratana raises $11.7M despite aborted stock offering American City Business Journals -14.22%
Mar-13-18 04:37PM  Aratana reports 4Q loss Associated Press
04:05PM  Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
07:58AM  When Can We Expect A Profit From Aratana Therapeutics Inc (NASDAQ:PETX)? Simply Wall St.
07:52AM  Aratana Therapeutics Q4 Earnings Preview Benzinga
Mar-02-18 04:05PM  Aratana builds pet drug pipeline by buying rights from Japanese company American City Business Journals
08:30AM  Aratana Therapeutics to Participate at Upcoming Investment Conferences PR Newswire
Mar-01-18 08:30AM  Aratana Therapeutics Expands Therapeutic Candidate Pipeline PR Newswire
Feb-13-18 08:30AM  Aratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results PR Newswire
Jan-18-18 08:00AM  GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017 PR Newswire
Jan-17-18 07:45AM  Investor Expectations to Drive Momentum within Enbridge Energy Management, Glacier, Energous, Aratana Therapeutics, Destination Maternity, and Super Micro Computer Discovering Underlying Factors of Influence GlobeNewswire
Jan-16-18 10:47AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jan-12-18 09:05AM  Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod Zacks
Jan-11-18 06:11PM  Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
08:19AM  Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe PR Newswire
Jan-03-18 02:02PM  3 Stocks That Feel Like Microsoft in 1986 Motley Fool
Dec-20-17 06:52PM  When will Kansas, Missouri exhaust funding for children's health insurance? American City Business Journals
08:05AM  Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic PR Newswire
Dec-18-17 03:00PM  Aratana's stock falls after newest pet drug treatment fails study American City Business Journals
Dec-15-17 04:15PM  Aratana Therapeutics Announces Study Results for AT-016 PR Newswire
Dec-08-17 01:19PM  ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017 Capital Cube
Nov-28-17 07:08PM  Aratana cancels stock offering after shares plunge MarketWatch -18.95%
06:56PM  Aratana Therapeutics, Inc. Announces Termination of Offering of Common Stock PR Newswire
04:30PM  Why Momo, Aratana Therapeutics, and Sea Limited Slumped Today Motley Fool
01:04PM  Why Aratana Therapeutics Inc. Is Tanking Today Motley Fool
Nov-27-17 04:10PM  Aratana Therapeutics, Inc. Announces Proposed Public Offering PR Newswire
Nov-24-17 10:49AM  ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017 Capital Cube
Nov-13-17 12:59PM  ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017 Capital Cube
Nov-10-17 11:31AM  Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe PR Newswire
Nov-07-17 03:10PM  With three products out, Aratana chases its fourth: a canine cancer drug American City Business Journals
08:21AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-03-17 12:26PM  ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017 Capital Cube +19.78%
06:20AM  Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 06:13PM  Aratana reports 3Q loss Associated Press
04:05PM  Aratana Therapeutics Reports Third Quarter 2017 Financial Results PR Newswire
12:02PM  What Does Aratana Therapeutics Incs (PETX) Share Price Indicate? Simply Wall St.
Oct-30-17 08:30AM  Aratana Therapeutics to Present at Credit Suisse Healthcare Conference PR Newswire
Oct-17-17 09:55AM  ETFs with exposure to Aratana Therapeutics, Inc. : October 17, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE
07:30AM  Corporate News Blog - Aratana Therapeutics Launches ENTYCE (Capromorelin Oral Solution) ACCESSWIRE
Oct-16-17 09:25AM  Hungry for growth, Aratana takes new pet drug to market American City Business Journals
Oct-13-17 04:05PM  Aratana Therapeutics Announces Launch of ENTYCE® (capromorelin oral solution) PR Newswire
Oct-05-17 04:30PM  Aratana Therapeutics to Report Third Quarter 2017 Financial Results PR Newswire +5.01%
Oct-03-17 11:30AM  ETFs with exposure to Aratana Therapeutics, Inc. : October 3, 2017 Capital Cube
Sep-22-17 11:16AM  ETFs with exposure to Aratana Therapeutics, Inc. : September 22, 2017 Capital Cube +5.61%
Sep-18-17 08:00AM  Aratana Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 12:42AM  ETFs with exposure to Aratana Therapeutics, Inc. : September 12, 2017 Capital Cube
Sep-08-17 04:10PM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 8, 2017 Capital Cube
Aug-13-17 10:50AM  Edited Transcript of PETX earnings conference call or presentation 4-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 03:47PM  Fast 50 CEOs talk about their different paths to rapid growth American City Business Journals
Aug-05-17 01:12AM  Aratana reports 2Q loss Associated Press
Aug-04-17 06:10AM  Investor Network: Aratana Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 04:30PM  Aratana Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
Jul-29-17 06:45AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jul-26-17 03:10PM  Aratana sniffs out new use for dog drug in cats American City Business Journals
08:30AM  Aratana Therapeutics Announces Positive Results for AT-003 PR Newswire
Jul-18-17 04:30PM  Aratana Therapeutics to Report Second Quarter 2017 Financial Results PR Newswire
Jul-07-17 03:22PM  ETFs with exposure to Aratana Therapeutics, Inc. : July 7, 2017 Capital Cube
Jun-26-17 04:40PM  ETFs with exposure to Aratana Therapeutics, Inc. : June 26, 2017 Capital Cube
Jun-16-17 04:11PM  ETFs with exposure to Aratana Therapeutics, Inc. : June 16, 2017 Capital Cube
Jun-14-17 09:35AM  Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
May-16-17 08:30AM  Aratana Therapeutics to Participate at Three Upcoming Investment Conferences PR Newswire
May-09-17 09:05PM  Edited Transcript of PETX earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
02:40PM  Aratana is tracking to hit canine drug milestone, fetches funds to build inventory American City Business Journals
07:15AM  Investor Network: Aratana Therapeutics, Inc. to Host Earnings Call Accesswire
May-08-17 05:19PM  Aratana reports 1Q loss Associated Press
04:30PM  Aratana Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
May-04-17 09:25AM  Biotech Movers: Aratana Offering Priced Below Market, Shares Fall TheStreet.com
May-03-17 07:29PM  Aratana Therapeutics Announces Pricing of Registered Direct Offering PR Newswire
Apr-25-17 04:30PM  Aratana Therapeutics Provides Update on ENTYCE® PR Newswire
Apr-24-17 08:30AM  Aratana Therapeutics to Report First Quarter 2017 Financial Results PR Newswire
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
St Peter StevenPRESIDENT AND CEOSep 21Sale6.0675,000454,305574,233Sep 21 06:31 PM
HEINEN ERNSTChief Development OfficerAug 14Sale5.151,7128,817155,694Aug 14 05:32 PM
HEINEN ERNSTChief Development OfficerAug 13Sale5.158,66044,599157,406Aug 14 05:32 PM
HEINEN ERNSTChief Development OfficerAug 10Sale5.151,95410,063166,066Aug 10 05:45 PM
HEINEN ERNSTChief Development OfficerAug 08Sale5.152,67413,771168,020Aug 10 05:45 PM
St Peter StevenPRESIDENT AND CEOJul 30Sale4.3311,51349,842649,233Jul 30 05:51 PM
Standridge BrentChief Operating OfficerJun 25Sale4.5610,00045,64499,967Jun 27 05:32 PM
St Peter StevenPRESIDENT AND CEOJan 30Sale4.7719,36792,301672,259Feb 01 05:29 PM
TOOMAN CRAIG ACHIEF FINANCIAL OFFICERJan 11Sale5.2730,000158,04075,024Jan 12 05:37 PM
TOOMAN CRAIG ACHIEF FINANCIAL OFFICERDec 21Option Exercise3.142,0006,280105,024Dec 21 06:09 PM
St Peter StevenPRESIDENT AND CEODec 20Option Exercise3.1426,66783,734556,026Dec 21 06:06 PM
Broadfin Healthcare Master Fun10% OwnerDec 01Sale5.44562,4283,059,3504,294,426Dec 01 05:01 PM
Broadfin Healthcare Master Fun10% OwnerNov 30Sale5.94211,5721,256,5914,856,854Dec 01 05:01 PM
Broadfin Healthcare Master Fun10% OwnerNov 29Sale6.53116,516761,1115,068,426Dec 01 05:01 PM
St Peter StevenPRESIDENT AND CEONov 10Sale7.0050,000350,000529,359Nov 13 06:05 PM